發送短信 : Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

 __   __    _____    __   __     ___      _____   
 \ \\/ //  |  ___||  \ \\/ //   / _ \\   |__  //  
  \   //   | ||__     \   //   / //\ \\    / //   
  / . \\   | ||__     / . \\  |  ___  ||  / //__  
 /_//\_\\  |_____||  /_//\_\\ |_||  |_|| /_____|| 
 `-`  --`  `-----`   `-`  --` `-`   `-`  `-----`